|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.28 HKD | -0.44% |
|
-4.39% | -14.18% |
| 06-12 | Sinopharm Group Co. Ltd. Approves Board Appointments | CI |
| 06-10 | Sinopharm Unit to Acquire 21% Stake in Pacific Shuanglin Bio-pharmacy | MT |
| Capitalization | 52.24B 57.05B 7.27B 6.34B 5.95B 5.41B 9.98B 631B 11.26B 70.23B 27.12B 288B 27.27B 26.69B 1,059B | P/E ratio 2025 * |
6.77x | P/E ratio 2026 * | 6.22x |
|---|---|---|---|---|---|
| Enterprise value | 20.43B 22.31B 2.84B 2.48B 2.33B 2.12B 3.9B 247B 4.4B 27.46B 10.6B 112B 10.66B 10.44B 414B | EV / Sales 2025 * |
0.03x | EV / Sales 2026 * | 0.04x |
| Free-Float |
42.99% | Yield 2025 * |
4.47% | Yield 2026 * | 4.77% |
More valuation ratios
* Estimated data
More news
More recommendations
| Sinopharm : 2024 Annual Results Presentation | 03-23 | PU |
| Sinopharm : 2024 Interim Report | 24-09-24 | PU |
| Sinopharm : 2024 Interim Results Presentation | 24-08-25 | PU |
| Sinopharm : 2023 Interim Results Presentation | 23-08-27 | PU |
| Sinopharm : 2022 Annual Results Presentation | 23-03-27 | PU |
More news
| 1 day | -0.44% | ||
| 1 week | -4.39% | ||
| Current month | -3.79% | ||
| 1 month | -0.98% | ||
| 3 months | -7.77% | ||
| 6 months | -15.76% | ||
| Current year | -14.18% |
| 1 week | 18.14 |  | 19.22 |
| 1 month | 18.14 | | 19.38 |
| Current year | 16.74 | | 21.35 |
| 1 year | 16.02 | | 23.65 |
| 3 years | 14.6 | | 28.45 |
| 5 years | 14.6 | | 28.45 |
| 10 years | 14.6 | | 45.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wan Yong Lian
PSD | President | 55 | 2024-08-26 |
Yi Jian Wu
SEC | Corporate Secretary | 55 | - |
Xiu Chang Jiang
DFI | Director of Finance/CFO | 61 | 2010-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Qi Yu Chen
BRD | Director/Board Member | 53 | 2010-04-30 |
Zheng Dong Liu
BRD | Director/Board Member | 55 | 2014-09-20 |
De Yong Wen
BRD | Director/Board Member | 53 | 2017-08-31 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 1.36% | 0 M€ | -19.71% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.44% | -4.39% | -12.74% | -0.44% | 7.3B | ||
| +0.63% | -0.26% | +20.89% | +142.51% | 91.2B | ||
| +0.30% | +3.04% | +58.90% | +226.23% | 39.48B | ||
| -1.09% | -2.15% | - | - | 24.39B | ||
| -0.15% | -5.12% | +35.28% | -2.44% | 10.04B | ||
| -0.45% | -5.50% | -9.08% | -3.79% | 8.19B | ||
| -1.19% | -7.58% | -3.68% | +10.08% | 5.46B | ||
| +0.29% | +0.58% | +17.21% | +29.84% | 5.24B | ||
| +0.41% | +0.49% | +16.46% | -5.08% | 4.55B | ||
| -1.17% | -7.34% | -1.56% | +14.58% | 3.54B | ||
| Average | -0.27% | -1.56% | +13.52% | +45.72% | 19.94B | |
| Weighted average by Cap. | +0.16% | +1.62% | +26.04% | +126.34% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 598B 653B 83.18B 72.53B 68.14B 61.96B 114B 7,225B 129B 804B 310B 3,291B 312B 305B 12,123B | 627B 685B 87.28B 76.11B 71.5B 65.02B 120B 7,581B 135B 844B 326B 3,454B 328B 321B 12,721B |
| Net income | 7.63B 8.34B 1.06B 926M 870M 791M 1.46B 92.23B 1.65B 10.26B 3.96B 42.02B 3.98B 3.9B 155B | 8.35B 9.12B 1.16B 1.01B 952M 865M 1.6B 101B 1.8B 11.23B 4.33B 45.97B 4.36B 4.27B 169B |
| Net Debt | -31.81B -34.74B -4.43B -3.86B -3.62B -3.3B -6.08B -384B -6.86B -42.77B -16.51B -175B -16.61B -16.25B -645B | -25.74B -28.11B -3.58B -3.12B -2.93B -2.67B -4.92B -311B -5.55B -34.61B -13.36B -142B -13.44B -13.15B -522B |
More financial data
* Estimated data
Employees
108,217
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-19 | 18.28 $ | -0.44% | 9,054,850 |
| 25-06-18 | 18.36 $ | -0.22% | 9,566,581 |
| 25-06-17 | 18.40 $ | -0.22% | 7,977,451 |
| 25-06-16 | 18.44 $ | -3.96% | 6,749,255 |
| 25-06-13 | 19.20 $ | +0.21% | 6,854,094 |
Delayed Quote Hong Kong S.E., June 19, 2025 at 04:08 am
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
16.74CNY
Average target price
20.35CNY
Spread / Average Target
+21.57%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1099 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition